[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350199-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350199-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","clonal-hematopoiesis-and-its-progression-to-myeloid-neoplasms-insights-into-risk-biology-and-therapeutic-strategies-review","Clonal hematopoiesis and its progression to myeloid neoplasms: insights into risk, biology, and therapeutic strategies - review","","Clonal hematopoiesis (CH) is defined by the clonal expansion of hematopoietic stem and progenitor cells carrying somatic mutations that provide a fitness advantage. CH is common with advancing age and becomes nearly ubiquitous in middle age. Despite often being asymptomatic, CH increases the risk of hematologic malignancies, especially myeloid neoplasms, plus diverse non-malignant conditions and all-cause mortality. The review synthesizes current knowledge on CH origins, determinants of clonal behavior, risk stratification, and emerging therapeutic strategies and trial design considerations.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/clonal-hematopoiesis-and-its-progression-to-myeloid-neoplasms-insights-into-risk-biology-and-therapeutic-strategies-review/350199/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/clonal-hematopoiesis-and-its-progression-to-myeloid-neoplasms-insights-into-risk-biology-and-therapeutic-strategies-review/350199.png","ImageObject",300,407,{"name":42,"@type":43},"Fahsai","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is clonal hematopoiesis (CH) and why is it clinically important?","Question",{"text":63,"@type":64},"CH is defined by clonal expansion of hematopoietic stem and progenitor cells that carry somatic mutations conferring a fitness advantage. Although often asymptomatic, CH is linked to increased risk of myeloid neoplasms, other adverse health outcomes, and higher all-cause mortality.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which factors can promote or influence the development of CH?",{"text":68,"@type":64},"Beyond aging, CH can be promoted by environmental exposures, inherited genetic predisposition, and acquired conditions. Large-scale population and longitudinal sequencing studies have identified determinants of clonal behavior.",{"name":70,"@type":61,"acceptedAnswer":71},"How do risk stratification models support therapeutic decision-making in CH?",{"text":72,"@type":64},"Characterizing CH natural history enables risk stratification models to identify individuals with CH at high risk of progression to myeloid neoplasms. This helps select patient populations most suitable for therapeutic intervention trials and supports emerging strategies such as targeting mutation-specific vulnerabilities and modulating inflammatory pathways.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350199,1790177979,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108,"preview_page_count":33,"preview_urls":145},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","REVIEW SERIES  \nClonal hematopoiesis and its progression to myeloid neoplasms: insights into risk, biology, and therapeutic strategies  \nJ. Scott Beeler, Matthew J. Walter and Kelly L. Bolton  \nDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA  \nCorrespondence: K. L. Bolton  \n[bolton@wustl.edu](bolton@wustl.edu)  \nReceived: September 29, 2025.  \nAccepted: January 23, 2026.  \nEarly view: February 5, 2026.  \n[https://doi.org/10.3324/haematol.2025.287488](https://doi.org/10.3324/haematol.2025.287488)  \n©2026 Ferrata Storti Foundation  \nPublished under a CC BY-NC license   \nAbstract  \nClonal hematopoiesis (CH) is defined by the clonal expansion of hematopoietic stem and progenitor cells harboring somatic mutations that confer a fitness advantage. CH is common with advancing age and becomes nearly ubiquitous in middle age. Although typically asymptomatic, CH is associated with an increased risk of hematologic malignancies particularly myeloid neoplasms (MN), diverse non-malignant conditions, and all-cause mortality. Over the past decade, research has provided major insights into the origins of CH. In addition to aging, CH is promoted by environmental exposures, inherited genetic predisposition, and acquired conditions. Large-scale population and longitudinal sequencing studies have identified determinants of clonal behavior. Characterization of the natural history of CH has enabled the development of risk stratification models to identify individuals with CH at high risk of progression to MN, thereby providing a rationale for selecting patient populations best suited for therapeutic intervention trials. Emerging strategies include targeting mutation-specific vulnerabilities, modulating inflammatory pathways, reducing genotoxic therapy-induced clonal selection, and repurposing agents with efficacy in MN. In this review, we summarize current knowledge of the risk factors underlying CH development, highlight recent advances in understanding the determinants of clonal behavior including progression to MN, and discuss emerging therapeutic approaches for preventing malignant transformation and clinical trial design considerations.  \nIntroduction  \nClonal hematopoiesis (CH) is characterized by the clonal expansion of hematopoietic stem and progenitor cells (HSPC). These clones arise through the acquisition of somatic DNA alterations, which confer a selective advantage and enable clonal outgrowth. The process of normal stem cells acquiring somatic mutations that modify fitness is pervasive across human tissues and increases with advancing age 1-3 A variety of DNA alterations can drive CH including point mutations, insertions-deletions (indels), and large-scale chromosomal changes (gains, losses, and copy-neutral loss of heterozygosity); the latter of which are termed mosaic chromosomal alterations.4,5 Most cases of CH are caused by point mutations in a small number of genes that are recurrently mutated in myeloid neoplasms (MN).6-8 These include genes involved in epigenetic modification (DNMT3A, TET2, ASXL1), DNA damage response (DDR; TP53 and PPM1D), RNA splicing (SRSF2, SF3B1,  \nU2AF1), and signal transduction (JAK2). CH is ubiquitous with aging and while typically clinically silent, is associated with an increased risk of progression to hematologic malignancies, including MN, as well as a variety of non-malignant adverse health outcomes which collectively result in increased allcause mortality.6,7 CH is a premalignant state, analogous to monoclonal gammopathy of undetermined significance, which offers a model for understanding the early stages of carcinogenesis in humans. Importantly, CH provides unique opportunities to study clonal dynamics and somatic mutation acquisition in humans since the peripheral blood allows for non-invasive sampling of the entire hematopoietic stem cell pool, which is not possible for other organ systems. This review summarizes current insights into the ","cbCaimOKv4PduR8y","https://ap.wps.com/l/cbCaimOKv4PduR8y","pdf",1089299,16,"English","# Abstract\n# Introduction\n# Key concepts and nomenclature of clonal hematopoiesis","[{\"question\":\"What is clonal hematopoiesis (CH) and why is it clinically important?\",\"answer\":\"CH is defined by clonal expansion of hematopoietic stem and progenitor cells that carry somatic mutations conferring a fitness advantage. Although often asymptomatic, CH is linked to increased risk of myeloid neoplasms, other adverse health outcomes, and higher all-cause mortality.\"},{\"question\":\"Which factors can promote or influence the development of CH?\",\"answer\":\"Beyond aging, CH can be promoted by environmental exposures, inherited genetic predisposition, and acquired conditions. Large-scale population and longitudinal sequencing studies have identified determinants of clonal behavior.\"},{\"question\":\"How do risk stratification models support therapeutic decision-making in CH?\",\"answer\":\"Characterizing CH natural history enables risk stratification models to identify individuals with CH at high risk of progression to myeloid neoplasms. This helps select patient populations most suitable for therapeutic intervention trials and supports emerging strategies such as targeting mutation-specific vulnerabilities and modulating inflammatory pathways.\"}]","Clonal hematopoiesis and its progression to myeloid neoplasms: insights into risk, biology, and therapeutic strategies - review | PDF",1790087693,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/666be34e6d3763ddb1d5a4eda2a52909.webp",983,1309,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e3a51eea21a26069f292bd6f5a60c110.webp",982,1308,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee030ab394b1eb74f1373525e9bb5ff5.webp",981,1306,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4925a72b64cfa59fbdd61f2499e34f82.webp",980,1305]